These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12801112)

  • 1. Treatment of children with Osteogenesis imperfecta in Estonia.
    Maasalu K; Haviko T; Märtson A
    Acta Paediatr; 2003 Apr; 92(4):452-5. PubMed ID: 12801112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral bisphosphonate treatment for osteogenesis imperfecta--an Indian perspective.
    Shah I; Johari A
    Ann Trop Paediatr; 2007 Mar; 27(1):39-43. PubMed ID: 17469731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of oral alendronate in children with osteogenesis imperfecta.
    Cho TJ; Choi IH; Chung CY; Yoo WJ; Park MS; Park YK
    J Pediatr Orthop; 2005; 25(5):607-12. PubMed ID: 16199940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EFFECTS OF LONG-TERM ALENDRONATE TREATMENT ON A LARGE SAMPLE OF PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA.
    Lv F; Liu Y; Xu X; Wang J; Ma D; Jiang Y; Wang O; Xia W; Xing X; Yu W; Li M
    Endocr Pract; 2016 Dec; 22(12):1369-1376. PubMed ID: 27482608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta.
    Dimeglio LA; Ford L; McClintock C; Peacock M
    J Pediatr Endocrinol Metab; 2005 Jan; 18(1):43-53. PubMed ID: 15679068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone densitometry in pediatric patients treated with pamidronate.
    Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
    Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.
    Chevrel G; Schott AM; Fontanges E; Charrin JE; Lina-Granade G; Duboeuf F; Garnero P; Arlot M; Raynal C; Meunier PJ
    J Bone Miner Res; 2006 Feb; 21(2):300-6. PubMed ID: 16418786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of alendronate on quality of life in children with osteogenesis imperfecta.
    Seikaly MG; Kopanati S; Salhab N; Waber P; Patterson D; Browne R; Herring JA
    J Pediatr Orthop; 2005; 25(6):786-91. PubMed ID: 16294137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
    Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
    Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of alendronate therapy in children with osteogenesis imperfecta.
    Vyskocil V; Pikner R; Kutílek S
    Joint Bone Spine; 2005 Oct; 72(5):416-23. PubMed ID: 16214075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alendronate treatment in children with osteogenesis imperfecta.
    Akcay T; Turan S; Guran T; Bereket A
    Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alendronate treatment in osteogenesis imperfecta.
    Madenci E; Yilmaz K; Yilmaz M; Coskun Y
    J Clin Rheumatol; 2006 Apr; 12(2):53-6. PubMed ID: 16601536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
    Ward LM; Rauch F; Whyte MP; D'Astous J; Gates PE; Grogan D; Lester EL; McCall RE; Pressly TA; Sanders JO; Smith PA; Steiner RD; Sullivan E; Tyerman G; Smith-Wright DL; Verbruggen N; Heyden N; Lombardi A; Glorieux FH
    J Clin Endocrinol Metab; 2011 Feb; 96(2):355-64. PubMed ID: 21106710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interventions for Improving Bone Mineral Density and Reducing Fracture Risk in Osteogenesis Imperfecta: A Mixed Treatment Comparison Network Meta-analysis of Randomized Controlled Clinical Trials.
    Sridharan K; Sivaramakrishnan G
    Curr Clin Pharmacol; 2018; 13(3):190-198. PubMed ID: 30160216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
    DiMeglio LA; Peacock M
    J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.
    Bargman R; Posham R; Boskey AL; DiCarlo E; Raggio C; Pleshko N
    Osteoporos Int; 2012 Mar; 23(3):1141-50. PubMed ID: 21901481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model.
    McCarthy EA; Raggio CL; Hossack MD; Miller EA; Jain S; Boskey AL; Camacho NP
    Pediatr Res; 2002 Nov; 52(5):660-70. PubMed ID: 12409511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study of oral alendronate in the treatment of pediatric osteogenesis imperfecta].
    Wei SS; Cai QX; Qiu WJ; Zhao L; Ye J; Wang XL; Chen Q; Gu XF
    Zhonghua Yi Xue Za Zhi; 2012 Jan; 92(4):246-9. PubMed ID: 22490796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
    Atta I; Iqbal F; Lone SW; Ibrahim M; Khan YN; Raza J
    J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.